PROVENTIL (albuterol) by Merck & Co. is clinical pharmacology the prime action of beta-adrenergic drugs is to stimulate adenyl cyclase, the enzyme which catalyzes the formation of cyclic-3',5'-adenosine monophosphate (cyclic amp) from adenosine triphosphate (atp). First approved in 1981.
Drug data last refreshed 16h ago · AI intelligence enriched 1w ago
PROVENTIL (albuterol) is a beta-2 adrenergic agonist inhaled as a metered-dose aerosol that rapidly relaxes bronchial smooth muscle. It is indicated for relief of bronchospasm in patients with reversible obstructive airway disease, including asthma and COPD. The drug works by stimulating adenyl cyclase to increase cyclic AMP, producing bronchodilation within 5 minutes with peak effect at approximately 1 hour.
As a legacy product approaching loss of exclusivity with moderate competitive pressure (30%), the brand team likely focuses on cost optimization and maintaining market share against generics rather than growth initiatives.
CLINICAL PHARMACOLOGY The prime action of beta-adrenergic drugs is to stimulate adenyl cyclase, the enzyme which catalyzes the formation of cyclic-3',5'-adenosine monophosphate (cyclic AMP) from adenosine triphosphate (ATP). The cyclic AMP thus formed mediates the cellular responses. In vitro…
Worked on PROVENTIL at Merck & Co.? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Efficacy of Nebulized Long-Acting Bronchodilators (Formoterol and Revefenacin) vs. Short-Acting Bronchodilators (Albuterol and Ipratropium) in Patients Presenting to the Emergency Department With Acute Exacerbation of COPD (ECOPD)
QUARTZ: Comparative Effectiveness of Switching From Albuterol to Albuterol/Budesonide Versus Adding Low-dose ICS or LTRA to Albuterol
A Randomized, Double-Blind, Placebo-Controlled Trial on Efficacy and Safety of Fluticasone Propionate/Albuterol Sulfate Combination in Participants 12 Years and Older With Asthma
Study to Investigate Changes in Airway Inflammation, Symptoms, and Rescue Therapy Utilization With AIRSUPRA Compared to Albuterol as Needed in Adults With Mild Asthma
Phase I PK Study of Budesonide/Albuterol Delivered From PT027 in Healthy Chinese Participants.
Upgrade to Pro to access CMS Part B ASP pricing data and other premium pharma intelligence.
Upgrade to Pro — $25/moWorking on PROVENTIL offers limited career growth due to its approaching loss of exclusivity and mature market position; roles focus on defending market share, managing generic transition, and ensuring regulatory compliance rather than growth initiatives. Professionals seeking advancement should view PROVENTIL assignments as stabilizing, cost-management focused positions best suited for mid-to-late career consolidation or transition preparation.